Search Results: Prevention, Detection & Risk + Pancreatic Cancer (7 results)
The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.
This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires.
For more information, visit the study website.
Breast, Ovarian, Prostate, Pancreatic, Melanoma
The PHACT study offers genetic testing to women and men of Ashkenazi (Eastern European) Jewish ancestry, age 21 or older. This group is at least ten times more likely than the general population to inherit certain kinds of genetic mutations associated with cancer risk. The study is open to people who live in one of the nine Bay Area counties (Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano, Sonoma). By participating in the UCSF Population Health and Cancer Testing (PHACT) study you will be provided with a saliva collection kit from Color Genomics, a genetic laboratory. Thirty genes will be analyzed, including BRCA1 and BRCA2, to identify mutations that increase the chance of cancer in both men and women of Ashkenazi (Eastern European) Jewish ancestry and genetic counseling support will be available with every test. For more information, visit the UCSF Center for BRCA Research.
A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up-To-Date Information About the Personal Importance of Genetic Testing (GEM)
The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.
Women interested in the study should contact the project coordinator, Mary Kate Ladd, by phone at (877) 687-2720 (toll-free) or by email.
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
Breast, Ovarian, Pancreatic, Prostate
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Pancreatic Cancer
|Clinical Trial||Official Title|
|NCT03250078||A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals|
|NCT03937453||A Pancreatic Cancer Screening Study in Individuals With New-Onset Diabetes Mellitus|
|NCT02478892||Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk|
|NCT03762590||GENetic Education Risk Assessment and TEsting Study|
|NCT03568630||Blood Markers of Early Pancreas Cancer|
|NCT02206360||Pancreatic Cancer Early Detection Program|
|NCT03851133||Florida Pancreas Collaborative Next Generation Biobank|
Research Search Tool Sponsored By:
Supported by a cooperative agreement from the
Patient Centered Outcomes Research Institute: PCORI EAIN-00055